WallStSmart

Edwards Lifesciences Corp (EW)vsSight Sciences Inc (SGHT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 7743% more annual revenue ($6.07B vs $77.36M). EW leads profitability with a 17.7% profit margin vs -49.7%. EW earns a higher WallStSmart Score of 55/100 (C).

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 2/9

SGHT

Avoid

29

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -1.72
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWSignificantly Overvalued (-544.4%)

Margin of Safety

-544.4%

Fair Value

$12.31

Current Price

$82.67

$70.36 premium

UndervaluedFair: $12.31Overvalued

Intrinsic value data unavailable for SGHT.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

SGHT0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
45.7x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-76.6%2/10

Earnings declined 76.6%

SGHT4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$187.40M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-50.7%2/10

ROE of -50.7% — below average capital efficiency

Free Cash FlowQuality
$-1.98M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.

Bull Case : SGHT

SGHT has a balanced fundamental profile.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.

Bear Case : SGHT

The primary concerns for SGHT are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

EW profiles as a mature stock while SGHT is a turnaround play — different risk/reward profiles.

SGHT carries more volatility with a beta of 2.43 — expect wider price swings.

EW is growing revenue faster at 13.3% — sustainability is the question.

EW generates stronger free cash flow (354M), providing more financial flexibility.

Bottom Line

EW scores higher overall (55/100 vs 29/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Sight Sciences Inc

HEALTHCARE · MEDICAL DEVICES · USA

Sight Sciences Inc. (SGHT) is a pioneering medical technology company focused on transforming the management of eye diseases through innovative surgical and non-surgical solutions, particularly targeting glaucoma care. With a robust portfolio of cutting-edge products and a strong intellectual property foundation, the company is strategically positioned to capitalize on the increasing demand for minimally invasive therapies in the ophthalmology sector. As Sight Sciences expands its distribution network and continues to drive advancements in eye care, it presents a compelling investment opportunity for institutional investors looking to engage with the dynamic healthcare market.

Want to dig deeper into these stocks?